Navigation Links
Model 583 Gel Dryer (220-240 V)

ProductsModel 583 Gel Dryer (220-240 V)
Company Bio-Rad Laboratories
Item Model 583 Gel Dryer (220-240 V)
Features 
Description The Model 583 gel dryer is an electrophoresis gel vacuum dryer that removes liquid from acrylamide and agarose gels and dries these gels onto cellophane or filter paper for long-term storage. The dryer incorporates lid-mounted heater elements which heat gels from above. The drying surface is 35 x 45 cm. This 220-240 V unit includes power cord, porous gel support, transparent sealing gasket, filter paper backing, cellophane membrane backing, sequencing gel filter paper, and instructions. Dimensions are 55 x 50 x 11 cm.
Info Bio-Rad Laboratories
Customer Service: 1-800-2-BIORAD
Web site: http://www.bio-rad.com

Related medicine products :

1. Reliance Stool, Model 5346
2. Reliance Stools, Model 5340
3. Reliance Stool, Model 5356
4. Reliance Stool, Model 5348
5. Pachymetric Analyzer Model 55
6. Model 1990 Dermatome
7. The New Model C Dermatome
8. NEW Padgett Model PI - Electro-Dermatome
9. Amo Phaco Model Diplomax
10. KR 4.22 Programmable Refrigerated Floor Model Centrifuge.
11. Model 420 UV Visible Spectrophotometer
...eg; UV-absorbing acrylic foldable single-piece pos... replacement of the human crystalline lens in the ...of age and older. The optical portion consists of ...se lenses have biconvex optics and supporting hapt...
Alcon introduces an intraocular lens that doesn't stop at UV filtration. Similar to the natural human lens, the new ACRYSOF® Natural IOL filters both UV and high-energy blue light. But while it f
All USIOL lenses are manufactured using the highest quality materials and processes. Perspex CQ UV PMMA material is used in the multi-piece and single piece lenses. Unioptic lens models are available
Single-Piece PMMA Intraocular Lenses.
Medicine Products:
(Date:5/16/2008)... HAE: TSX, MONTREAL...ation,(TSX:HAE), a specialty bio-therapeutics comp...rcialization, announced today that its Chairman of...li, will present at the,upcoming Rodman & Renshaw ..., May 20, 2008 in the Zephyr Room at Le Meridien B...
(Date:5/16/2008)... SAO PAULO, Brazil, May 16 /PRNewswire-FirstCall/ ...rs: TEMP3.SA; Bloomberg: TEMP3 BZ), a leading,prov... benefit plans and,specialized assistance services...r of 2008. The operating and financial information...d, is presented in Brazilian Reais and in,accordan...
(Date:5/15/2008)...PHILADELPHIA) Combining natural organic atoms wit...ute have developed a new type of enzyme inhibitor ...ys a key role in cancer development. , Based on...es the way for developing new ways to treat cancer...leads to uncontrolled tumor growth. , Details of...
(Date:5/15/2008)... HARBIN, China, May 15 /Xinhua-PRNewswire-FirstCal...tin Board: CYXI) ("China Yingxia" or "the,Company"...y engaged in the,development, manufacture and dist...plements, and personal care products in the People...inancial results for the first,quarter ended March...
Breaking Medicine News(10 mins):Health News:Haemacure announces webcast of presentation at Rodman & Renshaw 5th Annual Global Healthcare Conference 2Health News:Novel enzyme inhibitor paves way for new cancer drug 2Health News:Novel enzyme inhibitor paves way for new cancer drug 3Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 2Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 3Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 4Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 5Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 6Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 7Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 8Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 9
...f proteins and performs the role of manufacture an...ene is none other than the cell nucleus//, which h...to be built. If a particular protein is to be manu...he nucleus. The nucleus consists of the RNA, a DNA...
...on delivery is known to offset birth trauma, fetal...evealed//. Researchers from the University of Tex...d that, one in 100 babies who have been delivered ... of injury during the process. The injuries range ...
...very that will help millions of tuberculosis patie...y say is faster//, cheaper and more accurate and a...the World Health Organization recommends the sputu...hich analyses the material expelled from the lungs...
...ed telemedicine researchers at University of Queen...alist medical care//, virtually shrinking ominous ... the blink of an eye. The robot named Eliza was c...h one of the world’s most renowned names in teleme...
Other Medicine News:Health News:The Living Cell – Manufacturing, Protecting and Thrivin 2Health News:Scientists Have Developed Faster, More Accurate TB Test 2Health News:Robots Help Bring Specialist Doctors To You In A Trice 2
(Date:5/15/2008)... France, May 15 /- Cerenis,Therapeuti...ompany,developing HDL-related compounds for the tr...today announced that it has completed a Phase I,cl...d product candidates.,CER-002 is a peroxisome prol...agonist in development for the treatment of cardio...
(Date:5/15/2008)... CenterWatch, a publishing and,information service...l,trials, finds that investigative sites are requi...) systems. More than 75% of respondents to a recen...trained on three or more,EDC systems. In addition,...eir EDC training had improved., State of the Clin...
(Date:5/15/2008)...wire-FirstCall/ -- Novavax, Inc. (Nasdaq:,NVAX) to...the Phase I/IIa,study of its pandemic influenza va...cts. Favorable interim results from the first phas...70 healthy adult volunteers, were,reported in Dece... vaccine,is well tolerated and immunogenic at the ...
(Date:5/15/2008)... Plan Positions Blue Cross Blue Shield of Mic...rt from HealthLeaders-Inter...ealthLeaders-InterStudy, the,leading provider of m...he,economy continues to stagnate in Michigan, Blue...uipped of all of its competitors to weather the,ec...
Breaking Medicine Technology:Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease 2CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence 2Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial 2Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial 3Blue Cross Blue Shield Of Michigan Battles Sluggish Economy With Diverse Product Lineup 2Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 1Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 2Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 3Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 4Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3446 5Phlo Reports Sharp Revenue Increase 3441 1Phlo Reports Sharp Revenue Increase 3441 2Cancer Cure Coalition Proposes Major Changes at the FDA 1404 1Cancer Cure Coalition Proposes Major Changes at the FDA 1404 2Cancer Cure Coalition Proposes Major Changes at the FDA 1404 3Lack of political will and the subordination of women are major barriers to tackling AIDS 12406 1Lack of political will and the subordination of women are major barriers to tackling AIDS 12406 2Lack of political will and the subordination of women are major barriers to tackling AIDS 12406 3Lack of political will and the subordination of women are major barriers to tackling AIDS 12406 4